Komboglyze

Metformin Hydrochloride, the active ingredient in Komboglyze, is a biguanide and DPP‑4 inhibitor presented as a tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adult patients, helping to control elevated blood glucose levels.

GNH USA supplies Komboglyze as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, with established quality assurance processes and regulatory compliance across EU and global markets, and delivering reliable product availability to meet the therapeutic needs of patients worldwide.

Komboglyze, a fixed‑dose oral antidiabetic medication, is employed to achieve better glycemic control in the management of type 2 diabetes mellitus.

- Type 2 diabetes mellitus: lowers fasting and post‑prandial glucose levels, helping patients reach individualized HbA1c targets when combined with diet and exercise. - Metformin intolerance or contraindication: offers DPP‑4 inhibition to maintain glucose regulation for patients who cannot use metformin at therapeutic doses. - Inadequate response to monotherapy: added to existing treatment regimens to further reduce blood glucose when a single agent fails to achieve desired control.

Komboglyze may be associated with a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Nausea: mild to moderate stomach upset, often transient. - Diarrhea: loose stools, usually transient and may cause dehydration if severe. - Headache: mild cranial discomfort and may be aggravated by stress. - Upper respiratory tract infection: symptoms such as sore throat or runny nose. - Abdominal discomfort: mild pain or cramping in the stomach area. - Decreased appetite: reduced desire to eat, may lead to weight loss.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially life‑threatening metabolic condition. - Pancreatitis: inflammation of the pancreas presenting with abdominal pain. - Severe hypersensitivity: rash, angioedema, or anaphylactic reactions. - Hepatic impairment: elevated liver enzymes or liver injury.

When prescribing Komboglyze, clinicians should consider several precautionary measures to ensure safe use. - Renal function: assess creatinine clearance before initiation and periodically thereafter. - Lactic acidosis risk: avoid in patients with severe hepatic impairment or conditions predisposing to hypoxia. - Hypoglycemia monitoring: caution when combined with insulin or sulfonylureas. - Pregnancy and lactation: use only if potential benefit justifies potential risk; consult obstetric specialist. - Drug interactions: review concomitant medications for major DPP‑4 inhibitor or metformin interactions. - Store at ambient temperature: keep below 25°C, retain original packaging, protect from moisture.

Komboglyze can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate acute renal failure when combined with metformin; discontinue metformin before and after imaging. - CYP3A4 strong inhibitors (e.g., ketoconazole, clarithromycin): increase saxagliptin exposure, raising risk of hypoglycemia.

Moderate Interactions (Monitor Closely): - Diuretics: may enhance metformin-associated lactic acidosis risk; monitor renal function. - Beta‑blockers: can mask hypoglycemia symptoms; observe blood glucose closely. - Alcohol: potentiates metformin's effect on lactate metabolism; advise limited intake.